Kathryn C. Zoon

CIK: 0001685720

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (66.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

EBS

Emergent BioSolutions Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

EBS
Emergent BioSolutions Inc.
May 1, 2026
Sale(S)
Direct
16.1K shares at avg. $8.36$135K
EBS
Emergent BioSolutions Inc.
May 1, 2026
Sale(S)
Direct
1.1K shares at avg. $8.97$9K
EBS
Emergent BioSolutions Inc.
Apr 30, 2026
Award(A)
Direct
25.3K shares-
EBS
Emergent BioSolutions Inc.
Aug 15, 2025
Sale(S)
Direct
7.1K shares at avg. $8.87$63K
EBS
Emergent BioSolutions Inc.
Apr 30, 2025
Award(A)
Direct
34.4K shares-
EBS
Emergent BioSolutions Inc.
Mar 12, 2025
Sale(S)
Direct
10K shares at avg. $5.73$57K

		Type	Shares	Price		Ownership
May 1, 2026	EBS Emergent BioSolutions Inc.	Sale(S)	16,145	$8.36	$134,972	Direct
May 1, 2026	EBS Emergent BioSolutions Inc.	Sale(S)	1,057	$8.97	$9,481	Direct
Apr 30, 2026	EBS Emergent BioSolutions Inc.	Award(A)	25,344	-	$0	Direct
Aug 15, 2025	EBS Emergent BioSolutions Inc.	Sale(S)	7,086	$8.87	$62,853	Direct
Apr 30, 2025	EBS Emergent BioSolutions Inc.	Award(A)	34,403	-	-	Direct
Mar 12, 2025	EBS Emergent BioSolutions Inc.	Sale(S)	10,000	$5.73	$57,300	Direct

1-6 of 6 transactions

About Zoon Kathryn C

Zoon Kathryn C (SEC CIK 0001685720) files insider reports with the SEC as Director of Emergent BioSolutions Inc. (EBS).

Signal8 holds 4 ownership filings by Zoon Kathryn C, all Form 4s, filed between Mar 12, 2025 and May 4, 2026. Those filings report 6 transactions, from Mar 12, 2025 to May 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Zoon Kathryn C's filings is in GAITHERSBURG, MD.

Recent filings by Zoon Kathryn C

May 1, 2026: Open-market sales of EBS shares (2 lines, Form 4, code S).
Apr 30, 2026: Grant or award of EBS shares (Form 4, code A).
Aug 15, 2025: Open-market sale of EBS shares (Form 4, code S).
Apr 30, 2025: Grant or award of EBS shares (Form 4, code A).
Mar 12, 2025: Open-market sale of EBS shares (Form 4, code S).

Other insiders filing for Emergent BioSolutions Inc. (EBS)

DeGolyer Donald W, Director
Williams Paul Anthony, SVP, Products Business
Duatschek Stephanie, EVP, CGO
LINDAHL RICHARD S, EVP, Chief Financial Officer
Glessner Coleen, EVP, Quality & Ethics, and CPL
Hartzel William, SVP, Bioservices

How to read Form 4 transaction codes